Efficacy and Safety Evaluation of Hemoglobin Control by Erythrocyte Stimulate Agent Recommendation Algorithm in Kidney Failure with Renal Replacement Therapy
- Conditions
- Diseases of the genitourinary system
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 250
Patients with end-stage renal disease who have been on hemodialysis for more than 6 months
- Patients with hemoglobin levels above 8.0 g/dL and below 14.0 g/dL
- Patients using or planning to use Darbepoetin alpha
- Adults over 19 years old and under 80 years old
- Patients weighing more than 40.0 kg and less than 100.0 kg
- Among the target subjects, patients whose voluntary consent procedure was confirmed after explanation of the clinical trial
- Patients who can collect clinical variables for the past 5 months from the time of study registration required for algorithm operation
- Patients temporarily receiving hemodialysis due to acute kidney disease
- Patients temporarily undergoing hemodialysis before transplantation
- Patients who have experienced blood transfusion within 3 months of participating in the study
- Patients with serious systemic condition
- Patients with low compliance, e.g., people with mental illness
- Patients withdrew from clinical trials
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the rate of reaching the target hemoglobin
- Secondary Outcome Measures
Name Time Method ESA dose/month;hemoglobin difference;success rate;failure rate;over-correction rate;transfusion;hospitalization